MedTrace Logo

Evaluation of Depression and Anxiety in Chemotherapy Patients

NCT03552731 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-04-04

No results posted yet for this study

Summary

This study will examine the existence and severity of depression and anxiety in patients undergoing chemotherapy at RUMC. Patients currently undergoing initial chemotherapy cycle will be compared to patients undergoing a subsequent chemotherapy cycle. Data will then be collected using standardized depression and anxiety scales to assess if these comorbidities exist and to what severity level. Data already collected for depression and anxiety in patients with chronic, but not cancer, illness will be used as a control.

The participants will be screened for signs of psychological distress using three self administered questionnaires: the Generalized Anxiety Disorder 7 item Scale (GAD7) and Patient Health Questionnaire (PHQ9). Demographic information about the participants, including medical and psychiatric history, will also be gathered from their medical records.

Conditions

  • Oncology Problem

Interventions

BEHAVIORAL

Surveys

GAD 7 Survey and PHQ 9 Interventional survey will be administered in both groups.

Sponsors & Collaborators

  • Richmond University Medical Center

    lead OTHER

Principal Investigators

  • Jakey Patwari, MD · Richmond University Medical Center

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-20
Primary Completion
2024-12-20
Completion
2025-12-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03552731 on ClinicalTrials.gov